Atazanavir-Induced Severe Episodes of Kidney Stones in an HIV-1-Infected Subject Characterized by a CYP3A Poor Metabolizer Phenotype
Stefano Rusconi, Roberta Gagliardini, Felicia Stefania Falvella, Dario Cattaneo, Valentina Di Cristo, Andrea De Luca, Massimiliano Fabbiani, Emilio Clementi, Massimo Galli & Simona Di Giambenedetto · Journal of Pharmaceutical Research International · 2014
Background: Atazanavir, an antiretroviral drug of the protease inhibitor class, is co-administered with ritonavir to inhibit atazanavir metabolism and decrease pharmacokinetic variability. Atazanavir is metabolised mainly by CYP3A4/5 enzymes. High CYP3A intersubject variability h...
Open access
Research Article
10.9734/BJPR/2014/14348